Wenyue Hu
University of Science and Technology of China(CN)Qilu University of Technology(CN)Beijing University of Chinese Medicine(CN)Shanghai University of Traditional Chinese Medicine(CN)Zhejiang Hospital(CN)Yueyang Hospital(CN)Shandong Academy of Sciences(CN)
Publications by Year
Research Areas
Advanced Breast Cancer Therapies, Lung Cancer Research Studies, Melanoma and MAPK Pathways, Lung Cancer Treatments and Mutations, Neuroendocrine Tumor Research Advances
Most-Cited Works
- → PF-06463922, an ALK/ROS1 Inhibitor, Overcomes Resistance to First and Second Generation ALK Inhibitors in Preclinical Models(2015)458 cited
- → Spectrum and Degree of CDK Drug Interactions Predicts Clinical Performance(2016)414 cited
- → PF-06463922 is a potent and selective next-generation ROS1/ALK inhibitor capable of blocking crizotinib-resistant ROS1 mutations(2015)268 cited
- → Mechanistic Investigation of Bone Marrow Suppression Associated with Palbociclib and its Differentiation from Cytotoxic Chemotherapies(2015)165 cited
- → Optimization of Orally Bioavailable Enhancer of Zeste Homolog 2 (EZH2) Inhibitors Using Ligand and Property-Based Design Strategies: Identification of Development Candidate (R)-5,8-Dichloro-7-(methoxy(oxetan-3-yl)methyl)-2-((4-methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-3,4-dihydroisoquinolin-1(2H)-one (PF-06821497)(2017)126 cited